Dosing & Uses
Dosage Forms & Strengths
tablet
- 50mg
- 100mg
- 150mg
- 300mg
tablet, extended-release
- 150mg
- 300mg
Depression
Initial 150 mg/day PO divided q8-12hr
Increase by 50 mg/day q3-7Days
Outpatient: No more than 400 mg/day
Inpatient: No more than 600 mg/day
Oleptro (extended-release)
- 150 mg PO HS initially; may increase by increments of 75 mg/day q3Days; not to exceed 375 mg/day
- Swallow whole or may break in half along scored line; do not chew or crush
Insomnia (Off-label)
50-100 mg PO qDay
Aggressive Behavior (Off-label)
Initial: 50 mg PO q12hr
Maintenance: 75-400 mg/day divided PO q6-12hr
Cocaine Withdrawal (Off-label)
150-200 mg PO qDay
Alcohol Withdrawal (Off-label)
100-600 mg/day divided PO
Prevention of Migraine (Off-label)
100 mg PO qDay
Dose considerations
MAO inhibitors: Do not administer trazodone within 14 days of administering a MAO inhibitor when treating a psychiatric disorder
Coadministration with MAO inhibitors linezolid or IV methylene blue: Trazodone not recommended in patients actively receiving linezolid or IV methylene blue; consider other interventions if treating psychiatric condition; if coadministration necessary, because benefits outweigh risks, monitor for serotonin syndrome for 2 weeks or until 24 hr after last dose of linezolid or IV methylene blue, whichever comes first; may resume trazodone 24 hr after last dose of linezolid or IV methylene blue
Dosage Forms & Strengths
tablet
- 50mg
- 100mg
- 150mg
- 300mg
tablet, extended-release
- 150mg
- 300mg
Depression (Off-label)
<6 years: Safety and efficacy not established
6-12 years: 1.5-2 mg/kg/day PO in divided doses initially; not to exceed 6 mg/kg/day divded q8hr
>12 years: 25-50 mg/day PO; increase by 100-150 mg in divided doses
See Black Box Warnings
Dravet Syndrome (Orphan)
Orphan designation for treatment of Dravet syndrome
Sponsor
- Epygenix Therapeutics, Inc; 140 E. Ridgewood Avenue, Suite 415 South Tower; Paramus, New Jersey 07652
Depression
Immediate release: 25-50 mgPO qHS; increase dose by 25-50 mg every three days if inpatient or every week if oupatient not to exceed 75-150 mg/day
Extended release: Experience limited; use 150 mg PO HS initially; may increase by increments of 75 mg/day q3Days; not to exceed 375 mg/day
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (17)
- arsenic trioxide
trazodone and arsenic trioxide both increase QTc interval. Contraindicated.
- disopyramide
trazodone and disopyramide both increase QTc interval. Contraindicated.
- eliglustat
trazodone increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.
- ibutilide
trazodone and ibutilide both increase QTc interval. Contraindicated.
- indapamide
trazodone and indapamide both increase QTc interval. Contraindicated.
- isocarboxazid
isocarboxazid and trazodone both increase serotonin levels. Contraindicated.
- lefamulin
lefamulin will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lefamulin is contraindicated with CYP3A substrates know to prolong the QT interval.
- pentamidine
trazodone and pentamidine both increase QTc interval. Contraindicated.
- phenelzine
phenelzine and trazodone both increase serotonin levels. Contraindicated.
- pimozide
trazodone and pimozide both increase QTc interval. Contraindicated.
- procainamide
trazodone and procainamide both increase QTc interval. Contraindicated.
- procarbazine
procarbazine and trazodone both increase serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.
- quinidine
quinidine and trazodone both increase QTc interval. Contraindicated.
- safinamide
trazodone, safinamide. Either increases toxicity of the other by serotonin levels. Contraindicated. Concomitant use could result in life-threatening serotonin syndrome.
- saquinavir
trazodone will decrease the level or effect of saquinavir by P-glycoprotein (MDR1) efflux transporter. Contraindicated.
saquinavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. - sotalol
trazodone and sotalol both increase QTc interval. Contraindicated.
- tranylcypromine
tranylcypromine and trazodone both increase serotonin levels. Contraindicated.
Serious - Use Alternative (181)
- abametapir
abametapir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.
- albuterol
trazodone, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- amiodarone
trazodone and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.
- amisulpride
trazodone and amisulpride both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.
- amitriptyline
amitriptyline and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and amitriptyline both increase serotonin levels. Avoid or Use Alternate Drug. - amoxapine
amoxapine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug. - anagrelide
anagrelide and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- apalutamide
apalutamide will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.
- apomorphine
apomorphine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- arformoterol
trazodone, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- aripiprazole
aripiprazole and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- artemether
artemether and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- artemether/lumefantrine
trazodone and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
artemether/lumefantrine and trazodone both increase QTc interval. Avoid or Use Alternate Drug. - asenapine
asenapine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- asenapine transdermal
asenapine transdermal and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- atomoxetine
atomoxetine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- bedaquiline
bedaquiline and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- benzphetamine
trazodone, benzphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- bosentan
bosentan will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- buprenorphine
buprenorphine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine buccal
buprenorphine buccal and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine subdermal implant
buprenorphine subdermal implant and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine transdermal
buprenorphine transdermal and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- bupropion
trazodone increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible.
- buspirone
trazodone and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- calcium/magnesium/potassium/sodium oxybates
trazodone, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- ceritinib
ceritinib and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
ceritinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. - chloramphenicol
chloramphenicol will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- chloroquine
chloroquine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- chlorpromazine
chlorpromazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- citalopram
citalopram and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- clarithromycin
clarithromycin will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
trazodone and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug. - clomipramine
clomipramine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug. - clonidine
trazodone decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.
- clozapine
clozapine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- cobicistat
cobicistat will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- conivaptan
conivaptan will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- crizotinib
crizotinib and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- cyclobenzaprine
trazodone and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- degarelix
degarelix and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- desflurane
desflurane and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- desipramine
desipramine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. - desvenlafaxine
trazodone and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.
- dexfenfluramine
trazodone, dexfenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dexmethylphenidate
trazodone, dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dextroamphetamine
trazodone, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dextromethorphan
trazodone and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.
- diethylpropion
trazodone, diethylpropion. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dobutamine
trazodone, dobutamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dofetilide
trazodone and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.
- donepezil
donepezil and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- dopamine
trazodone, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dopexamine
trazodone, dopexamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dosulepin
trazodone and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.
- doxepin
doxepin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and doxepin both increase serotonin levels. Avoid or Use Alternate Drug. - dronedarone
trazodone and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.
- droperidol
trazodone and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- duloxetine
duloxetine and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- efavirenz
efavirenz and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- eliglustat
eliglustat and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- encorafenib
encorafenib and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- entrectinib
trazodone and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.
- ephedrine
trazodone, ephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- epinephrine
epinephrine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone, epinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - epinephrine racemic
epinephrine racemic and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone, epinephrine racemic. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - eribulin
eribulin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin base
trazodone and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin ethylsuccinate
trazodone and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin lactobionate
trazodone and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin stearate
trazodone and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.
- escitalopram
escitalopram and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- etravirine
etravirine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- fenfluramine
trazodone, fenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- fexinidazole
fexinidazole and trazodone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.
fexinidazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates. - fingolimod
fingolimod and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- fluconazole
trazodone and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.
- fluoxetine
fluoxetine and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- fluphenazine
fluphenazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- fluvoxamine
fluvoxamine and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- formoterol
trazodone and formoterol both increase QTc interval. Avoid or Use Alternate Drug.
trazodone, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - fosamprenavir
fosamprenavir increases levels of trazodone by decreasing metabolism. Avoid or Use Alternate Drug.
- gemifloxacin
gemifloxacin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- gilteritinib
gilteritinib and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- glasdegib
trazodone and glasdegib both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, monitor for increased risk of QTc interval prolongation.
- granisetron
granisetron and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- guanfacine
trazodone decreases effects of guanfacine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.
- haloperidol
trazodone and haloperidol both increase QTc interval. Avoid or Use Alternate Drug.
- hydroxyzine
hydroxyzine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- idelalisib
idelalisib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates
- imipramine
imipramine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and imipramine both increase serotonin levels. Avoid or Use Alternate Drug. - inotuzumab
inotuzumab and trazodone both increase QTc interval. Avoid or Use Alternate Drug. If unable to avoid concomitant use, obtain ECGs and electrolytes before and after initiation of any drug known to prolong QTc, and periodically monitor as clinically indicated during treatment.
- isoflurane
isoflurane and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- isoproterenol
trazodone, isoproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- itraconazole
itraconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
trazodone and itraconazole both increase QTc interval. Avoid or Use Alternate Drug. - ivosidenib
ivosidenib will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
- ketoconazole
ketoconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
trazodone and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug. - levalbuterol
trazodone, levalbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- levoketoconazole
levoketoconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
trazodone and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug. - levomilnacipran
levomilnacipran and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- linezolid
linezolid and trazodone both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
- lisdexamfetamine
trazodone, lisdexamfetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- lithium
lithium and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- lofepramine
lofepramine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug. - lonafarnib
trazodone will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.
lonafarnib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration with sensitive CYP3A substrates. If coadministration unavoidable, monitor for adverse reactions and reduce CYP3A substrate dose in accordance with product labeling. - lopinavir
lopinavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- lorcaserin
trazodone and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.
- lumefantrine
trazodone and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug.
- maprotiline
maprotiline and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug. - meperidine
trazodone and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.
- metaproterenol
trazodone, metaproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- methylene blue
methylene blue and trazodone both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.
- methylenedioxymethamphetamine
trazodone, methylenedioxymethamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- midodrine
trazodone, midodrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- mifepristone
mifepristone will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- milnacipran
milnacipran and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- mirtazapine
mirtazapine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- moxifloxacin
trazodone and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- nefazodone
nefazodone will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
nefazodone and trazodone both increase serotonin levels. Avoid or Use Alternate Drug. - nevirapine
nevirapine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- nilotinib
trazodone and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.
- norepinephrine
trazodone, norepinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- nortriptyline
nortriptyline and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug. - octreotide
trazodone and octreotide both increase QTc interval. Avoid or Use Alternate Drug.
- octreotide (Antidote)
trazodone and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.
- olanzapine
olanzapine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- olopatadine intranasal
trazodone and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- oxaliplatin
oxaliplatin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- ozanimod
ozanimod increases levels of trazodone by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.
- panobinostat
trazodone and panobinostat both increase QTc interval. Avoid or Use Alternate Drug. Panobinostat is known to significantly prolong QT interval. Panobinostat prescribing information states use with drugs known to prolong QTc is not recommended.
- paroxetine
paroxetine and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- perphenazine
perphenazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- phendimetrazine
trazodone, phendimetrazine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phentermine
trazodone, phentermine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
trazodone, phentermine. Either increases toxicity of the other by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of serotonin syndrome. - phenylephrine
trazodone, phenylephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenylephrine PO
trazodone, phenylephrine PO. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- pirbuterol
trazodone, pirbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- pitolisant
trazodone and pitolisant both increase QTc interval. Avoid or Use Alternate Drug.
- pomalidomide
trazodone decreases levels of pomalidomide by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.
- posaconazole
posaconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- primaquine
primaquine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- promazine
promazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- propylhexedrine
trazodone, propylhexedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- protriptyline
protriptyline and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and protriptyline both increase serotonin levels. Avoid or Use Alternate Drug. - pseudoephedrine
trazodone, pseudoephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- rasagiline
rasagiline and trazodone both increase serotonin levels. Avoid or Use Alternate Drug. Trazodone should not be coadministered with a MAOI or within 14 days of discontinuing a MAOI. Similarly, a MAOI should not be given within 14 days of stopping trazodone.
- ribociclib
ribociclib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- rifabutin
rifabutin will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- rifampin
rifampin will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- rifapentine
rifapentine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- salmeterol
trazodone, salmeterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- selegiline
selegiline and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- selegiline transdermal
selegiline transdermal and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
- serdexmethylphenidate/dexmethylphenidate
trazodone, serdexmethylphenidate/dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- sertraline
sertraline and trazodone both increase serotonin levels. Avoid or Use Alternate Drug.
sertraline and trazodone both increase QTc interval. Avoid or Use Alternate Drug. - sevoflurane
sevoflurane and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- siponimod
siponimod and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- sodium oxybate
trazodone, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- solifenacin
solifenacin and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- St John's Wort
St John's Wort will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
trazodone and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug. - sunitinib
sunitinib and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- tacrolimus
tacrolimus and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- tedizolid
tedizolid, trazodone. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.
- terbutaline
trazodone, terbutaline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- tetrabenazine
tetrabenazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- thioridazine
thioridazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- tipranavir
tipranavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- toremifene
trazodone and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
- trifluoperazine
trifluoperazine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- trimipramine
trazodone and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug. - tucatinib
tucatinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.
- venlafaxine
trazodone and venlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.
- vilazodone
trazodone, vilazodone. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.
- voriconazole
voriconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- vorinostat
vorinostat and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
- vortioxetine
trazodone increases toxicity of vortioxetine by serotonin levels. Avoid or Use Alternate Drug.
- voxelotor
voxelotor will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.
- xylometazoline
trazodone, xylometazoline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- yohimbe
yohimbe, trazodone. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.
- yohimbine
trazodone, yohimbine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- ziprasidone
trazodone and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.
Monitor Closely (424)
- 5-HTP
trazodone and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.
- aceclofenac
trazodone, aceclofenac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- acemetacin
trazodone, acemetacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- aclidinium
aclidinium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- acrivastine
acrivastine and trazodone both increase sedation. Use Caution/Monitor.
- albuterol
trazodone increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and trazodone both increase QTc interval. Use Caution/Monitor. - alfentanil
alfentanil and trazodone both increase sedation. Use Caution/Monitor.
- aliskiren
trazodone will decrease the level or effect of aliskiren by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- almotriptan
almotriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.
- alprazolam
alprazolam and trazodone both increase sedation. Use Caution/Monitor.
- amikacin
trazodone will decrease the level or effect of amikacin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- amisulpride
amisulpride and trazodone both increase sedation. Use Caution/Monitor.
- amitriptyline
trazodone will decrease the level or effect of amitriptyline by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
amitriptyline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
amitriptyline and trazodone both increase sedation. Use Caution/Monitor. - amobarbital
amobarbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
amobarbital and trazodone both increase sedation. Use Caution/Monitor. - amoxapine
amoxapine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and trazodone both increase sedation. Use Caution/Monitor. - apomorphine
trazodone and apomorphine both increase sedation. Use Caution/Monitor.
- aprepitant
aprepitant will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- arformoterol
trazodone increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and trazodone both increase QTc interval. Use Caution/Monitor. - aripiprazole
aripiprazole and trazodone both increase sedation. Use Caution/Monitor.
- armodafinil
armodafinil will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. - artemether/lumefantrine
artemether/lumefantrine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- asenapine
asenapine and trazodone both increase sedation. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and trazodone both increase sedation. Use Caution/Monitor.
- aspirin
trazodone, aspirin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- aspirin rectal
trazodone, aspirin rectal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- aspirin/citric acid/sodium bicarbonate
trazodone, aspirin/citric acid/sodium bicarbonate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- atazanavir
atazanavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
atazanavir increases levels of trazodone by unspecified interaction mechanism. Use Caution/Monitor. - atogepant
trazodone will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- atorvastatin
trazodone will decrease the level or effect of atorvastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- atracurium
atracurium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- atropine IV/IM
atropine IV/IM and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- avapritinib
trazodone will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
avapritinib and trazodone both increase sedation. Use Caution/Monitor. - axitinib
trazodone increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- azelastine
azelastine and trazodone both increase sedation. Use Caution/Monitor.
- azithromycin
trazodone and azithromycin both increase QTc interval. Use Caution/Monitor.
- baclofen
baclofen and trazodone both increase sedation. Use Caution/Monitor.
- bazedoxifene/conjugated estrogens
trazodone will decrease the level or effect of bazedoxifene/conjugated estrogens by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- belladonna and opium
belladonna and opium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
belladonna and opium and trazodone both increase sedation. Use Caution/Monitor. - benperidol
benperidol and trazodone both increase sedation. Use Caution/Monitor.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, trazodone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
benzhydrocodone/acetaminophen and trazodone both increase sedation. Use Caution/Monitor. - benzphetamine
trazodone increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexpiprazole
trazodone will increase the level or effect of brexpiprazole by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor.
brexpiprazole and trazodone both increase sedation. Use Caution/Monitor. - brimonidine
brimonidine and trazodone both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and trazodone both increase sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and trazodone both increase sedation. Use Caution/Monitor.
- budesonide
budesonide will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of budesonide by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - bupivacaine implant
trazodone, bupivacaine implant. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia.
- buprenorphine
buprenorphine and trazodone both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
buprenorphine buccal and trazodone both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
trazodone, buprenorphine subdermal implant. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
buprenorphine subdermal implant and trazodone both increase sedation. Use Caution/Monitor. - buprenorphine transdermal
buprenorphine transdermal and trazodone both increase sedation. Use Caution/Monitor.
- buprenorphine, long-acting injection
trazodone, buprenorphine, long-acting injection. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
- butabarbital
butabarbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
butabarbital and trazodone both increase sedation. Use Caution/Monitor. - butalbital
butalbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
butalbital and trazodone both increase sedation. Use Caution/Monitor. - butorphanol
butorphanol and trazodone both increase sedation. Use Caution/Monitor.
- caffeine
trazodone increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbamazepine
carbamazepine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will increase the level or effect of carbamazepine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor plasma levels when used concomitantly - carbinoxamine
carbinoxamine and trazodone both increase sedation. Use Caution/Monitor.
- carisoprodol
carisoprodol and trazodone both increase sedation. Use Caution/Monitor.
- celecoxib
trazodone, celecoxib. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- chloral hydrate
chloral hydrate and trazodone both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and trazodone both increase sedation. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and trazodone both increase sedation. Use Caution/Monitor.
- chlorpromazine
chlorpromazine and trazodone both increase sedation. Use Caution/Monitor.
- chlorzoxazone
chlorzoxazone and trazodone both increase sedation. Use Caution/Monitor.
- choline magnesium trisalicylate
trazodone, choline magnesium trisalicylate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- cimetidine
cimetidine will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- cinnarizine
cinnarizine and trazodone both increase sedation. Use Caution/Monitor.
- citalopram
citalopram and trazodone both increase serotonin levels. Use Caution/Monitor. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.
- clemastine
clemastine and trazodone both increase sedation. Use Caution/Monitor.
- clomipramine
clomipramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
clomipramine and trazodone both increase sedation. Use Caution/Monitor. - clonazepam
clonazepam and trazodone both increase sedation. Use Caution/Monitor.
- clorazepate
clorazepate and trazodone both increase sedation. Use Caution/Monitor.
- clozapine
clozapine and trazodone both increase sedation. Use Caution/Monitor.
- cobicistat
cobicistat will increase the level or effect of trazodone by Other (see comment). Use Caution/Monitor. Trazodone is a substrate of CYP3A4 and CYP2D6; cobicistat inhibits CYP3A4 and CYP2D6
- cocaine topical
trazodone and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.
- codeine
codeine and trazodone both increase sedation. Use Caution/Monitor.
- conjugated estrogens
trazodone will decrease the level or effect of conjugated estrogens by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- conjugated estrogens, vaginal
trazodone will decrease the level or effect of conjugated estrogens, vaginal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- cortisone
cortisone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of cortisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - crizotinib
crizotinib increases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
- crofelemer
crofelemer increases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.
- cyclizine
cyclizine and trazodone both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
cyclobenzaprine and trazodone both increase sedation. Use Caution/Monitor.
- cyclosporine
cyclosporine will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- cyproheptadine
cyproheptadine and trazodone both increase sedation. Use Caution/Monitor.
- dabrafenib
dabrafenib will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
- dantrolene
dantrolene and trazodone both increase sedation. Use Caution/Monitor.
- daridorexant
trazodone and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darifenacin
darifenacin will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- darunavir
darunavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with SSRIs, TCAs, or trazodone may require dose titration of antidepressant to desired effect (eg, using the lowest feasible initial or maintenance dose). Monitor for antidepressant response.
- dasatinib
dasatinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely. - daunorubicin
trazodone will decrease the level or effect of daunorubicin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- debrisoquine
trazodone decreases effects of debrisoquine by Other (see comment). Use Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.
- deferasirox
deferasirox will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- deflazacort
trazodone will decrease the level or effect of deflazacort by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- desflurane
desflurane and trazodone both increase sedation. Use Caution/Monitor.
- desipramine
desipramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and trazodone both increase sedation. Use Caution/Monitor. - deutetrabenazine
deutetrabenazine and trazodone both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation).
- dexamethasone
dexamethasone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - dexchlorpheniramine
dexchlorpheniramine and trazodone both increase sedation. Use Caution/Monitor.
- dexfenfluramine
trazodone increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
trazodone and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely. - dexmedetomidine
dexmedetomidine and trazodone both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
trazodone increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
trazodone increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
trazodone and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.
trazodone increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor. - dextroamphetamine transdermal
trazodone, dextroamphetamine transdermal. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s).
- dextromoramide
dextromoramide and trazodone both increase sedation. Use Caution/Monitor.
- diamorphine
diamorphine and trazodone both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and trazodone both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, trazodone. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- diclofenac
trazodone, diclofenac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- diethylpropion
trazodone increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and trazodone both increase sedation. Use Caution/Monitor.
- difenoxin hcl
difenoxin hcl and trazodone both increase sedation. Use Caution/Monitor.
- diflunisal
trazodone, diflunisal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- digoxin
trazodone will decrease the level or effect of digoxin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
trazodone increases levels of digoxin by unspecified interaction mechanism. Use Caution/Monitor. - dihydroergotamine
trazodone and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- dihydroergotamine intranasal
trazodone and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.
- diltiazem
diltiazem will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- dimenhydrinate
dimenhydrinate and trazodone both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine and trazodone both increase sedation. Use Caution/Monitor.
- diphenoxylate hcl
diphenoxylate hcl and trazodone both increase sedation. Use Caution/Monitor.
- dipipanone
dipipanone and trazodone both increase sedation. Use Caution/Monitor.
- dobutamine
trazodone increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- docetaxel
trazodone will decrease the level or effect of docetaxel by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- dolasetron
trazodone and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.
- dopamine
trazodone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
trazodone increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- doxepin
doxepin and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
doxepin and trazodone both increase sedation. Use Caution/Monitor. - doxorubicin
trazodone will decrease the level or effect of doxorubicin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- doxorubicin liposomal
trazodone will decrease the level or effect of doxorubicin liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- doxylamine
doxylamine and trazodone both increase sedation. Use Caution/Monitor.
- dronedarone
dronedarone will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- droperidol
droperidol and trazodone both increase sedation. Use Caution/Monitor.
- duvelisib
duvelisib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with duvelisib increases AUC of a sensitive CYP3A4 substrate which may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitor for signs of toxicities of the coadministered sensitive CYP3A substrate.
- efavirenz
efavirenz will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- elagolix
elagolix decreases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.
- eletriptan
eletriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.
- elvitegravir/cobicistat/emtricitabine/tenofovir DF
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.
- encorafenib
encorafenib, trazodone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents.
- enzalutamide
enzalutamide will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ephedrine
trazodone increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
trazodone increases effects of ephedrine by unknown mechanism. Use Caution/Monitor. - epinephrine
trazodone increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
trazodone increases effects of epinephrine by unknown mechanism. Use Caution/Monitor. - epinephrine racemic
trazodone increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
trazodone increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor. - ergotamine
trazodone and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- erythromycin base
erythromycin base will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- erythromycin ethylsuccinate
erythromycin ethylsuccinate will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- erythromycin lactobionate
erythromycin lactobionate will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- erythromycin stearate
erythromycin stearate will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- eslicarbazepine acetate
eslicarbazepine acetate will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- estazolam
estazolam and trazodone both increase sedation. Use Caution/Monitor.
- estradiol
trazodone will decrease the level or effect of estradiol by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- estrogens conjugated synthetic
trazodone will decrease the level or effect of estrogens conjugated synthetic by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- estropipate
trazodone will decrease the level or effect of estropipate by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- ethanol
trazodone and ethanol both increase sedation. Use Caution/Monitor.
- etodolac
trazodone, etodolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- etomidate
etomidate and trazodone both increase sedation. Use Caution/Monitor.
- etoposide
trazodone will decrease the level or effect of etoposide by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- everolimus
trazodone will decrease the level or effect of everolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- fedratinib
fedratinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.
- fenbufen
trazodone, fenbufen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- fenfluramine
trazodone increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
trazodone and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.
fenfluramine, trazodone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. - fenoprofen
trazodone, fenoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- finerenone
trazodone will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.
- flecainide
trazodone and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.
- flibanserin
trazodone will increase the level or effect of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors.
- fluconazole
fluconazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- fludrocortisone
fludrocortisone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of fludrocortisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - fluoxetine
trazodone and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- fluphenazine
fluphenazine and trazodone both increase sedation. Use Caution/Monitor.
- flurazepam
flurazepam and trazodone both increase sedation. Use Caution/Monitor.
- flurbiprofen
trazodone, flurbiprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- fluvoxamine
fluvoxamine and trazodone both increase QTc interval. Modify Therapy/Monitor Closely.
- formoterol
trazodone increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fosamprenavir
fosamprenavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
- fosaprepitant
fosaprepitant will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- foscarnet
trazodone and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.
- fosphenytoin
fosphenytoin will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- fostemsavir
trazodone and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- frovatriptan
frovatriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.
- gabapentin
gabapentin, trazodone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, trazodone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- ganaxolone
trazodone and ganaxolone both increase sedation. Use Caution/Monitor.
- gemtuzumab
trazodone and gemtuzumab both increase QTc interval. Use Caution/Monitor.
- gentamicin
trazodone will decrease the level or effect of gentamicin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- goserelin
goserelin increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- grapefruit
grapefruit will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- green tea
green tea, trazodone. Other (see comment). Use Caution/Monitor. Comment: Combination may increase risk of bleeding.
- griseofulvin
griseofulvin will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- haloperidol
haloperidol and trazodone both increase sedation. Use Caution/Monitor.
- henbane
henbane and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- histrelin
histrelin increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- homatropine
homatropine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hydrocodone
hydrocodone, trazodone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- hydrocortisone
hydrocortisone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of hydrocortisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - hydromorphone
hydromorphone and trazodone both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and trazodone both increase sedation. Use Caution/Monitor.
- hyoscyamine
hyoscyamine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- hyoscyamine spray
hyoscyamine spray and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ibuprofen
trazodone, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- ibuprofen IV
trazodone, ibuprofen IV. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- iloperidone
trazodone and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.
iloperidone and trazodone both increase sedation. Use Caution/Monitor.
iloperidone increases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4. - imatinib
trazodone will decrease the level or effect of imatinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- imipramine
imipramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
imipramine and trazodone both increase sedation. Use Caution/Monitor. - indinavir
indinavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
trazodone will decrease the level or effect of indinavir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - indomethacin
trazodone, indomethacin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- ipratropium
ipratropium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- irinotecan liposomal
trazodone will decrease the level or effect of irinotecan liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- isavuconazonium sulfate
trazodone will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- isoniazid
isoniazid will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely. - isoproterenol
trazodone increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- istradefylline
istradefylline will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
- itraconazole
trazodone will decrease the level or effect of itraconazole by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- ivermectin
trazodone will decrease the level or effect of ivermectin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- ketamine
ketamine and trazodone both increase sedation. Use Caution/Monitor.
- ketoprofen
trazodone, ketoprofen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- ketorolac
trazodone, ketorolac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- ketorolac intranasal
trazodone, ketorolac intranasal. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- ketotifen, ophthalmic
trazodone and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- L-tryptophan
trazodone and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.
- lapatinib
lapatinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of lapatinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
trazodone and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely. - lasmiditan
lasmiditan, trazodone. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
trazodone will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification.
- lenacapavir
lenacapavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.
- lenvatinib
trazodone and lenvatinib both increase QTc interval. Use Caution/Monitor. Lenvatinib prescribing information recommends monitoring ECG closely when coadministered with QT prolonging drugs.
- leuprolide
leuprolide increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- levalbuterol
trazodone increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levofloxacin
trazodone and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- levorphanol
levorphanol and trazodone both increase sedation. Use Caution/Monitor.
- linagliptin
trazodone will decrease the level or effect of linagliptin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a P-gp inducer.
- lisdexamfetamine
trazodone increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lithium
trazodone and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.
- lofepramine
lofepramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
lofepramine and trazodone both increase sedation. Use Caution/Monitor. - lofexidine
trazodone and lofexidine both increase sedation. Use Caution/Monitor.
trazodone decreases effects of lofexidine by unspecified interaction mechanism. Use Caution/Monitor. - lomitapide
trazodone increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.
- loperamide
trazodone will decrease the level or effect of loperamide by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- loprazolam
loprazolam and trazodone both increase sedation. Use Caution/Monitor.
- lorazepam
lorazepam and trazodone both increase sedation. Use Caution/Monitor.
- lorlatinib
lorlatinib will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- lormetazepam
lormetazepam and trazodone both increase sedation. Use Caution/Monitor.
- lornoxicam
trazodone, lornoxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- lovastatin
trazodone will decrease the level or effect of lovastatin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- loxapine
loxapine and trazodone both increase sedation. Use Caution/Monitor.
- loxapine inhaled
loxapine inhaled and trazodone both increase sedation. Use Caution/Monitor.
- lsd
trazodone and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.
- lumefantrine
lumefantrine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- lurasidone
lurasidone, trazodone. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
maprotiline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
maprotiline and trazodone both increase sedation. Use Caution/Monitor. - maraviroc
trazodone will decrease the level or effect of maraviroc by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- marijuana
marijuana will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone and marijuana both increase sedation. Use Caution/Monitor. - meclizine
meclizine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- meclofenamate
trazodone, meclofenamate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- mefenamic acid
trazodone, mefenamic acid. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- melatonin
trazodone and melatonin both increase sedation. Use Caution/Monitor.
- meloxicam
trazodone, meloxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- meperidine
meperidine and trazodone both increase sedation. Use Caution/Monitor.
- meprobamate
trazodone and meprobamate both increase sedation. Use Caution/Monitor.
- mestranol
trazodone will decrease the level or effect of mestranol by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- metaproterenol
trazodone increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
metaxalone and trazodone both increase sedation. Use Caution/Monitor.
- methadone
trazodone and methadone both increase QTc interval. Modify Therapy/Monitor Closely.
methadone and trazodone both increase sedation. Use Caution/Monitor. - methamphetamine
trazodone increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. trazodone increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Significant - Monitor Closely..
methamphetamine increases toxicity of trazodone by Other (see comment). Use Caution/Monitor. Comment: Amphetamines may increase the toxicity of serotonin modulators, increasing the risk of serotonin syndrome. . - methocarbamol
methocarbamol and trazodone both increase sedation. Use Caution/Monitor.
- methscopolamine
methscopolamine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methylenedioxymethamphetamine
trazodone increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methylphenidate
methylphenidate increases toxicity of trazodone by Other (see comment). Modify Therapy/Monitor Closely. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity.
- methylprednisolone
methylprednisolone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of methylprednisolone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - metronidazole
metronidazole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- miconazole vaginal
miconazole vaginal will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- midazolam
midazolam and trazodone both increase sedation. Use Caution/Monitor.
- midazolam intranasal
trazodone will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation.
- midodrine
trazodone increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mipomersen
mipomersen, trazodone. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.
- mirtazapine
trazodone and mirtazapine both increase sedation. Use Caution/Monitor.
trazodone and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely. - mitotane
mitotane decreases levels of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.
- modafinil
trazodone increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
morphine and trazodone both increase sedation. Use Caution/Monitor.
trazodone and morphine both increase serotonin levels. Modify Therapy/Monitor Closely. - motherwort
trazodone and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
trazodone and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
trazodone and nabilone both increase sedation. Use Caution/Monitor.
- nabumetone
trazodone, nabumetone. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- nafcillin
nafcillin will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- nalbuphine
nalbuphine and trazodone both increase sedation. Use Caution/Monitor.
- naproxen
trazodone, naproxen. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- naratriptan
naratriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.
- nefopam
nefopam, trazodone. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Use combination with caution.
- nelfinavir
nelfinavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of nelfinavir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - neomycin PO
trazodone will decrease the level or effect of neomycin PO by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- nifedipine
nifedipine will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- nilotinib
nilotinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of nilotinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - nirmatrelvir
nirmatrelvir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adverse reactions of nausea, dizziness, hypotension, and syncope observed following coadministration of trazodone and strong CYP3A4 inhibitors. Consider lower trazodone dose.
- nirmatrelvir/ritonavir
nirmatrelvir/ritonavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adverse reactions of nausea, dizziness, hypotension, and syncope observed following coadministration of trazodone and strong CYP3A4 inhibitors. Consider lower trazodone dose.
- norepinephrine
trazodone increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
trazodone increases effects of norepinephrine by unknown mechanism. Use Caution/Monitor. - nortriptyline
nortriptyline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
nortriptyline and trazodone both increase sedation. Use Caution/Monitor. - ofloxacin
trazodone and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- olanzapine
olanzapine and trazodone both increase sedation. Use Caution/Monitor.
- oliceridine
trazodone will increase the level or effect of oliceridine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.
trazodone, oliceridine. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. - opium tincture
opium tincture and trazodone both increase sedation. Use Caution/Monitor.
- orphenadrine
trazodone and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
orphenadrine and trazodone both increase sedation. Use Caution/Monitor. - osilodrostat
osilodrostat and trazodone both increase QTc interval. Use Caution/Monitor.
- oxaliplatin
oxaliplatin will increase the level or effect of trazodone by Other (see comment). Use Caution/Monitor. Monitor for ECG changes if therapy is initiated in patients with drugs known to prolong QT interval.
- oxaprozin
trazodone, oxaprozin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- oxazepam
oxazepam and trazodone both increase sedation. Use Caution/Monitor.
- oxcarbazepine
oxcarbazepine will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- oxybutynin
oxybutynin and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
oxybutynin topical and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
oxybutynin transdermal and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxycodone
oxycodone and trazodone both increase sedation. Use Caution/Monitor.
- oxymorphone
oxymorphone and trazodone both increase sedation. Use Caution/Monitor.
- paclitaxel
trazodone will decrease the level or effect of paclitaxel by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- paclitaxel protein bound
trazodone will decrease the level or effect of paclitaxel protein bound by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- paliperidone
trazodone will decrease the level or effect of paliperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
trazodone and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.
paliperidone and trazodone both increase sedation. Use Caution/Monitor. - pancuronium
pancuronium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- papaveretum
papaveretum and trazodone both increase sedation. Use Caution/Monitor.
- papaverine
trazodone and papaverine both increase sedation. Use Caution/Monitor.
- parecoxib
trazodone, parecoxib. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- paromomycin
trazodone will decrease the level or effect of paromomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- paroxetine
trazodone and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- pazopanib
trazodone and pazopanib both increase QTc interval. Use Caution/Monitor.
- peginterferon alfa 2b
peginterferon alfa 2b, trazodone. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.
- pentazocine
pentazocine and trazodone both increase sedation. Use Caution/Monitor.
trazodone and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely. - pentobarbital
pentobarbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital and trazodone both increase sedation. Use Caution/Monitor. - perphenazine
perphenazine and trazodone both increase sedation. Use Caution/Monitor.
- phendimetrazine
trazodone increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenobarbital
phenobarbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
phenobarbital and trazodone both increase sedation. Use Caution/Monitor. - phentermine
trazodone increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
trazodone increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine ophthalmic
trazodone, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenylephrine PO
trazodone increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
trazodone and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
pimozide and trazodone both increase sedation. Use Caution/Monitor.
- pirbuterol
trazodone increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- piroxicam
trazodone, piroxicam. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- posaconazole
trazodone will decrease the level or effect of posaconazole by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
trazodone and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely. - pralidoxime
pralidoxime and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- prednisolone
trazodone will decrease the level or effect of prednisolone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- prednisone
prednisone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will decrease the level or effect of prednisone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - pregabalin
pregabalin, trazodone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- primidone
primidone will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
primidone and trazodone both increase sedation. Use Caution/Monitor. - prochlorperazine
prochlorperazine and trazodone both increase QTc interval. Use Caution/Monitor.
prochlorperazine and trazodone both increase sedation. Use Caution/Monitor. - promethazine
promethazine and trazodone both increase QTc interval. Use Caution/Monitor.
promethazine and trazodone both increase sedation. Use Caution/Monitor. - propantheline
propantheline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- propofol
propofol and trazodone both increase sedation. Use Caution/Monitor.
- propylhexedrine
trazodone increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
protriptyline and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
protriptyline and trazodone both increase sedation. Use Caution/Monitor. - quazepam
quazepam and trazodone both increase sedation. Use Caution/Monitor.
- quetiapine
quetiapine and trazodone both increase sedation. Use Caution/Monitor.
- quinupristin/dalfopristin
quinupristin/dalfopristin will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- ramelteon
trazodone and ramelteon both increase sedation. Use Caution/Monitor.
- ranolazine
trazodone and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely.
- rapacuronium
rapacuronium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- remimazolam
remimazolam, trazodone. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
- rifabutin
rifabutin decreases levels of trazodone by increasing metabolism. Use Caution/Monitor.
- risperidone
trazodone will decrease the level or effect of risperidone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
trazodone and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.
risperidone and trazodone both increase sedation. Use Caution/Monitor. - ritonavir
ritonavir will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.
trazodone will decrease the level or effect of ritonavir by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. - rizatriptan
rizatriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.
- rocuronium
rocuronium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- romidepsin
trazodone will decrease the level or effect of romidepsin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- rucaparib
rucaparib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated.
- rufinamide
rufinamide will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- salicylates (non-asa)
trazodone, salicylates (non-asa). Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- salmeterol
trazodone increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- salsalate
trazodone, salsalate. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- SAMe
trazodone and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.
- scopolamine
scopolamine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scullcap
trazodone and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
secobarbital and trazodone both increase sedation. Use Caution/Monitor. - sevoflurane
sevoflurane and trazodone both increase sedation. Use Caution/Monitor.
- shepherd's purse
trazodone and shepherd's purse both increase sedation. Use Caution/Monitor.
- silodosin
trazodone will decrease the level or effect of silodosin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- sirolimus
trazodone will decrease the level or effect of sirolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- solifenacin
solifenacin and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- stiripentol
stiripentol, trazodone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.
- streptomycin
trazodone will decrease the level or effect of streptomycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- sufentanil
sufentanil and trazodone both increase sedation. Use Caution/Monitor.
- sufentanil SL
sufentanil SL, trazodone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- sulfamethoxazole
trazodone and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- sulfasalazine
trazodone, sulfasalazine. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- sulindac
trazodone, sulindac. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- sumatriptan
sumatriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.
- sumatriptan intranasal
sumatriptan intranasal and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.
- tacrolimus
trazodone will decrease the level or effect of tacrolimus by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- tamsulosin
trazodone increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- tapentadol
tapentadol and trazodone both increase sedation. Use Caution/Monitor.
trazodone and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely. - tazemetostat
tazemetostat will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone will increase the level or effect of tazemetostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. - tecovirimat
tecovirimat will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.
- telavancin
trazodone and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- temazepam
temazepam and trazodone both increase sedation. Use Caution/Monitor.
- terbutaline
trazodone increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
thioridazine and trazodone both increase sedation. Use Caution/Monitor.
- thiothixene
thiothixene and trazodone both increase sedation. Use Caution/Monitor.
- tinidazole
trazodone will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- tiotropium
tiotropium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tobramycin
trazodone will decrease the level or effect of tobramycin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- tolfenamic acid
trazodone, tolfenamic acid. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- tolmetin
trazodone, tolmetin. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of upper GI bleeding. SSRIs inhib. serotonin uptake by platelets.
- tolterodine
tolterodine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tolvaptan
trazodone will decrease the level or effect of tolvaptan by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- topiramate
topiramate will decrease the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
trazodone and topiramate both increase sedation. Modify Therapy/Monitor Closely. - tramadol
tramadol and trazodone both increase sedation. Use Caution/Monitor.
trazodone and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely. - triazolam
triazolam and trazodone both increase sedation. Use Caution/Monitor.
- triclabendazole
triclabendazole and trazodone both increase QTc interval. Use Caution/Monitor.
- triclofos
triclofos and trazodone both increase sedation. Use Caution/Monitor.
- trifluoperazine
trifluoperazine and trazodone both increase sedation. Use Caution/Monitor.
- trimethoprim
trazodone and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.
- trimipramine
trazodone and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
trazodone and trimipramine both increase sedation. Use Caution/Monitor. - triprolidine
triprolidine and trazodone both increase sedation. Use Caution/Monitor.
- triptorelin
triptorelin increases toxicity of trazodone by QTc interval. Use Caution/Monitor. Increases risk of torsades de pointes.
- tropisetron
trazodone and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.
- trospium chloride
trospium chloride and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- valbenazine
valbenazine and trazodone both increase QTc interval. Use Caution/Monitor.
- vecuronium
vecuronium and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
- venlafaxine
trazodone and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.
- verapamil
verapamil will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- vinblastine
trazodone will decrease the level or effect of vinblastine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- vincristine
trazodone will decrease the level or effect of vincristine by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- vincristine liposomal
trazodone will decrease the level or effect of vincristine liposomal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.
- voriconazole
trazodone and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- xylometazoline
trazodone increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
trazodone increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
trazodone and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
ziprasidone and trazodone both increase sedation. Use Caution/Monitor.
- zolmitriptan
zolmitriptan and trazodone both increase serotonin levels. Modify Therapy/Monitor Closely.
Minor (131)
- acarbose
trazodone increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.
- acetazolamide
acetazolamide will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- almotriptan
trazodone, almotriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.
- alvimopan
trazodone will decrease the level or effect of alvimopan by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- amobarbital
amobarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- anastrozole
anastrozole will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- anticholinergic/sedative combos
anticholinergic/sedative combos and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- armodafinil
trazodone will decrease the level or effect of armodafinil by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- atorvastatin
trazodone increases levels of atorvastatin by unspecified interaction mechanism. Minor/Significance Unknown.
- atropine
atropine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
trazodone increases levels of atropine by unknown mechanism. Minor/Significance Unknown. - atropine IV/IM
trazodone increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.
- bazedoxifene/conjugated estrogens
bazedoxifene/conjugated estrogens, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- belladonna alkaloids
belladonna alkaloids and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- benztropine
benztropine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- bethanechol
bethanechol increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- brimonidine
trazodone decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- bumetanide
bumetanide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.
- butabarbital
butabarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- butalbital
butalbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- carbachol
carbachol increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- carbamazepine
carbamazepine decreases levels of trazodone by increasing metabolism. Minor/Significance Unknown.
- celandine
celandine decreases effects of trazodone by pharmacodynamic antagonism. Minor/Significance Unknown. Based on animal studies.
- cevimeline
cevimeline increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- chlorpromazine
trazodone, chlorpromazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, chlorpromazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - chlorpropamide
trazodone increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.
- cisatracurium
cisatracurium and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- conjugated estrogens
conjugated estrogens, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- conjugated estrogens, vaginal
conjugated estrogens, vaginal, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- cyclizine
cyclizine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- cyclobenzaprine
cyclobenzaprine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- cyclophosphamide
cyclophosphamide will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- darifenacin
darifenacin and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- desflurane
desflurane, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- dexmethylphenidate
dexmethylphenidate increases effects of trazodone by decreasing metabolism. Minor/Significance Unknown.
- DHEA, herbal
DHEA, herbal will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- dicyclomine
dicyclomine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- diphenhydramine
diphenhydramine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- donepezil
donepezil increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- echothiophate iodide
echothiophate iodide increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- eletriptan
trazodone, eletriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.
- estradiol
estradiol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- estrogens conjugated synthetic
estrogens conjugated synthetic, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- estrogens esterified
estrogens esterified, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- estropipate
estropipate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- ethacrynic acid
ethacrynic acid, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.
- ethanol
ethanol, trazodone. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive impairment of motor skills.
- ethinylestradiol
ethinylestradiol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.
- ethotoin
trazodone increases levels of ethotoin by unspecified interaction mechanism. Minor/Significance Unknown.
- etomidate
etomidate, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- eucalyptus
trazodone and eucalyptus both increase sedation. Minor/Significance Unknown.
- fesoterodine
fesoterodine and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- fexofenadine
trazodone will decrease the level or effect of fexofenadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- flavoxate
flavoxate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- fluphenazine
trazodone, fluphenazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - fosphenytoin
trazodone increases levels of fosphenytoin by unspecified interaction mechanism. Minor/Significance Unknown.
- frovatriptan
trazodone, frovatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.
- furosemide
furosemide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.
- galantamine
galantamine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- glimepiride
trazodone increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.
- glipizide
trazodone increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.
- glyburide
trazodone increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.
- glycopyrrolate
glycopyrrolate and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- glycopyrrolate inhaled
glycopyrrolate inhaled and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
trazodone increases levels of glycopyrrolate inhaled by unknown mechanism. Minor/Significance Unknown. - hydroxyprogesterone caproate (DSC)
hydroxyprogesterone caproate (DSC), trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- insulin aspart
trazodone increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin detemir
trazodone increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin glargine
trazodone increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin glulisine
trazodone increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin lispro
trazodone increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin NPH
trazodone increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin regular human
trazodone increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.
- isoproterenol
isoproterenol, trazodone. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.
- ketamine
ketamine, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- larotrectinib
larotrectinib will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- lithium
lithium, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.
trazodone, lithium. Mechanism: unknown. Minor/Significance Unknown. Risk of neurotoxicity. - loratadine
trazodone will decrease the level or effect of loratadine by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.
- lovastatin
trazodone increases levels of lovastatin by unspecified interaction mechanism. Minor/Significance Unknown.
- mestranol
mestranol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- metformin
trazodone increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.
- miglitol
trazodone increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.
- naratriptan
trazodone, naratriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.
- nateglinide
trazodone increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.
- neostigmine
neostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- onabotulinumtoxinA
onabotulinumtoxinA and trazodone both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- panax ginseng
panax ginseng increases effects of trazodone by pharmacodynamic synergism. Minor/Significance Unknown.
- pentobarbital
pentobarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- perphenazine
trazodone, perphenazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - phenobarbital
phenobarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- phenytoin
trazodone increases levels of phenytoin by unspecified interaction mechanism. Minor/Significance Unknown.
- physostigmine
physostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- pilocarpine
pilocarpine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- pioglitazone
trazodone increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
- pitavastatin
trazodone increases levels of pitavastatin by unspecified interaction mechanism. Minor/Significance Unknown.
- pleurisy root
pleurisy root decreases effects of trazodone by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.
- pravastatin
trazodone increases levels of pravastatin by unspecified interaction mechanism. Minor/Significance Unknown.
- primidone
primidone, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- prochlorperazine
trazodone, prochlorperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - progesterone micronized
progesterone micronized, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- promazine
trazodone, promazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - promethazine
trazodone, promethazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - propofol
propofol, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- pyridostigmine
pyridostigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- repaglinide
trazodone increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.
- rivastigmine
rivastigmine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- rizatriptan
trazodone, rizatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.
- rosiglitazone
trazodone increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
- rosuvastatin
trazodone increases levels of rosuvastatin by unspecified interaction mechanism. Minor/Significance Unknown.
- ruxolitinib
trazodone will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- ruxolitinib topical
trazodone will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- sage
trazodone and sage both increase sedation. Minor/Significance Unknown.
- saxagliptin
trazodone increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- secobarbital
secobarbital, trazodone. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- serdexmethylphenidate/dexmethylphenidate
serdexmethylphenidate/dexmethylphenidate increases effects of trazodone by decreasing metabolism. Minor/Significance Unknown.
- sevoflurane
sevoflurane, trazodone. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- simvastatin
trazodone increases levels of simvastatin by unspecified interaction mechanism. Minor/Significance Unknown.
- sitagliptin
trazodone increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- succinylcholine
succinylcholine increases and trazodone decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- sulfamethoxazole
sulfamethoxazole decreases levels of trazodone by unspecified interaction mechanism. Minor/Significance Unknown.
- sumatriptan
trazodone, sumatriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.
- sumatriptan intranasal
trazodone, sumatriptan intranasal. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.
- thioridazine
trazodone, thioridazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - tolazamide
trazodone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.
- tolbutamide
trazodone increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.
- torsemide
torsemide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.
- trifluoperazine
trazodone, trifluoperazine. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
trazodone, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. - vasopressin
trazodone increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.
- verapamil
verapamil increases levels of trazodone by decreasing metabolism. Minor/Significance Unknown.
- vildagliptin
trazodone increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- zafirlukast
zafirlukast will increase the level or effect of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- zolmitriptan
trazodone, zolmitriptan. Mechanism: unknown. Minor/Significance Unknown. Risk of weakness, dyspnea, chest pain.
- zolpidem
zolpidem, trazodone. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.
Adverse Effects
>10%
Blurred vision (5-15%)
Dizziness (20-28%)
Drowsiness (24-40%)
Dry mouth (15-34%)
Fatigue (6-15%)
Headache (10-33%)
Nausea/vomiting (10-21%)
1-10%
Constipation (7-8%)
Edema (3-7%)
Confusion (5-6%)
Disorientation (<2%)
Incoordination (2-5%)
Nasal congestion (3-6%)
Orthostatic hypotension (<7%)
Syncope (<5%)
Tremor (1-5%)
Weight change (5%)
Ejaculation disorder (2%)
Decreased libido (1-2%)
<1%
Priapism
Sedation
Alopecia
Anxiety
Acne
Anemia
Increased apetite
Diplopia
Insomnia
Urinary retention
Vertigo
Warnings
Black Box Warnings
In short-term studies, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (<24 yr of age) taking antidepressants for major depressive disorders and other psychiatric illnesses
This increase was not seen in patients aged >24 years; a slight decrease in suicidal thinking was seen in adults >65 years
In children and young adults, risks must be weighed against the benefits of taking antidepressants
Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies; this should be done during initial 1-2 months of therapy and dosage adjustments
The patient’s family should communicate any abrupt changes in behavior to the healthcare provider
Worsening behavior and suicidal tendencies that are not part of the presenting symptoms may require discontinuation of therapy
This drug is not FDA approved for use in pediatric patients or for treatment of bipolar depression
Contraindications
Hypersensitivity
Coadministration with serotonergic drugs
- Risk of serotonin syndrome when coadministered within 14 days of MAOIs, or coadministered with other strong serotonergic drugs (eg, SNRIs, SSRIs)
- Starting trazodone in a patient who is being treated with linezolid or IV methylene blue is contraindicated because of an increased risk of serotonin syndrome
- If linezolid or IV methylene blue must be administered, discontinue trazodone immediately and monitor for CNS toxicity; may resume clomipramine 24 hr after last linezolid or methylene blue dose or after 2 weeks of monitoring, whichever comes first
Cautions
Administer shortly after meal; if drowsiness occurs, decrease dosage or give most of divided dosage HS
Discontinue if prolonged or inappropriate erection occurs
Discontinue if neutropenia, leukopenia
Use caution in patients with risk of seizures
Clinical worsening and suicide ideation may occur despite medication in adolescents and young adults (18-24 years)
Perform leukocyte and differential with fever, sore throat, or other signs of infection
Discontinue if leukocytes/ANC decreases below normal range
Coadministration with MAO inhibitors: risk of serotonin syndrome
Drugs that interfere with serotonin reuptake have been associated with bleeding; trazodone may also impair platelet aggregation resulting in increased risk of bleeding events
Potentially life-threatening serotonin syndrome reported when coadministered with drugs that impair serotonin metabolism (in particular, MAOIs, including nonpsychiatric MAOIs, such as linezolid and IV methylene blue) (see Contraindications)
Coadministration with NSAIDs and aspirin, may increase risk of bleeding
Bone fractures associated with antidepressant treatments
Increases risk of hyponatremia
Use caution in patients with risk of seizures including head trauma, alcoholism, brain damage
May worsen psychosis in patients or precipitate mania or hypomania; screen, for bipolar disorder, patients presenting with depressive symptoms
May cause orthostatic hypotension and syncope; use wiht caution
QT prolongation with or without torsade de pointes and ventricular tachycardia reported
May increase risk associated with electroconvulsive therapy (ECT); discontinue ECT before initiating trazodone therapy
Risk of mydriasis; may trigger angle closure attack in patients with angle closure glaucoma with anatomically narrow angles without a patent iridectomy
Pregnancy & Lactation
Pregnancy
Published prospective cohort studies, case series, and case reports over several decades with use in pregnant women have not identified drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes
Drug has been shown to cause increased fetal resorption and other adverse effects on fetus in rat when given at dose levels approximately 7.3 to 11 times the maximum recommended human dose (MRHD) of 400 mg/day in adults on a mg/m² basis; there was also an increase in congenital anomalies in the rabbit at approximately 7.3 to 22 times the MRHD on a mg/m² basis
Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum
Lactation
Data from published literature report the transfer of trazodone into human milk; there are no data on effect on milk production; limited data from postmarketing reports have not identified an association of adverse effects on breastfed child
The developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child or from underlying maternal condition
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Antidepressant structurally unrelated to SSRIs, tricyclics, tetracyclics or MAOIs, but also inhibits neuronal uptake of serotonin (but not NE); it is a histamine and alpha1-adrenergic receptor antagonist; causes adrenoceptor subsensitivity
Absorption
Almost completely absorbed (increased by food)
Onset: 6 weeks (antidepressant); 1-3 hr sleep aid
Peak serum time: 30-100 min (up to 2.5 hr if taken with food); 9 hr (extended release)
Concentration: 480-1620 ng/mL (dose-dependent)
Distribution
Protein bound: 85-95%
Metabolism
Metabolism: hepatic P450 enzyme CYP3A4 (major) CYP2D6 (minor)
Metabolites: l-m-chlorophenylpiperazine
Elimination
Half-life: 7-10 hr
Excretion: Urine (75%); feces (25%)
Dialyzable: No
Administration
Oral Administration
Take with food
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
trazodone oral - | 100 mg tablet | ![]() | |
trazodone oral - | 150 mg tablet | ![]() | |
trazodone oral - | 50 mg tablet | ![]() | |
trazodone oral - | 150 mg tablet | ![]() | |
trazodone oral - | 50 mg tablet | ![]() | |
trazodone oral - | 150 mg tablet | ![]() | |
trazodone oral - | 100 mg tablet | ![]() | |
trazodone oral - | 50 mg tablet | ![]() | |
trazodone oral - | 50 mg tablet | ![]() | |
trazodone oral - | 100 mg tablet | ![]() | |
trazodone oral - | 100 mg tablet | ![]() | |
trazodone oral - | 150 mg tablet | ![]() | |
trazodone oral - | 50 mg tablet | ![]() | |
trazodone oral - | 300 mg tablet | ![]() | |
trazodone oral - | 50 mg tablet | ![]() | |
trazodone oral - | 100 mg tablet | ![]() | |
trazodone oral - | 150 mg tablet | ![]() | |
trazodone oral - | 300 mg tablet | ![]() | |
trazodone oral - | 100 mg tablet | ![]() | |
trazodone oral - | 150 mg tablet | ![]() | |
trazodone oral - | 300 mg tablet | ![]() | |
trazodone oral - | 300 mg tablet | ![]() | |
trazodone oral - | 300 mg tablet | ![]() | |
trazodone oral - | 300 mg tablet | ![]() |
Copyright © 2010 First DataBank, Inc.
Patient Handout
trazodone oral
TRAZODONE - ORAL
(TRAZ-oh-done)
COMMON BRAND NAME(S): Desyrel
WARNING: Antidepressant medications are used to treat a variety of conditions, including depression and other mental/mood disorders. These medications can help prevent suicidal thoughts/attempts and provide other important benefits. However, studies have shown that a small number of people (especially people younger than 25) who take antidepressants for any condition may experience worsening depression, other mental/mood symptoms, or suicidal thoughts/attempts. It is very important to talk with the doctor about the risks and benefits of antidepressant medication (especially for people younger than 25), even if treatment is not for a mental/mood condition.Tell the doctor right away if you notice worsening depression/other psychiatric conditions, unusual behavior changes (including possible suicidal thoughts/attempts), or other mental/mood changes (including new/worsening anxiety, panic attacks, trouble sleeping, irritability, hostile/angry feelings, impulsive actions, severe restlessness, very rapid speech). Be especially watchful for these symptoms when a new antidepressant is started or when the dose is changed.
USES: This medication is used to treat depression. It may help to improve your mood, appetite, and energy level as well as decrease anxiety and insomnia related to depression. Trazodone works by helping to restore the balance of a certain natural chemical (serotonin) in the brain.
HOW TO USE: Read the Medication Guide provided by your pharmacist before you start using trazodone and each time you get a refill. If you have any questions, consult your doctor or pharmacist.Take this medication by mouth after a meal or snack as directed by your doctor, usually once or twice daily. If drowsiness is a problem and you are taking 1 dose daily, take it at bedtime. If you are taking 2 doses each day, it may help to take 1 of the doses at bedtime. Follow your doctor's directions carefully.Dosage is based on your medical condition and response to treatment. To reduce your risk of side effects, your doctor may start you at a low dose and gradually increase your dose.Take this medication exactly as prescribed. Do not increase your dose or take this medication more often than prescribed. Your condition will not improve any faster, and the risk of serious side effects may be increased.Keep taking this medication as prescribed even if you feel well. To help you remember, take it at the same time(s) each day. Do not stop taking this medication without consulting your doctor. Anxiety, agitation, and trouble sleeping can occur if the drug is suddenly stopped.It may take 2 to 4 weeks before you notice the full effects of this medication. Tell your doctor if your condition lasts or gets worse.
SIDE EFFECTS: See also the Warning section.Nausea, vomiting, diarrhea, drowsiness, dizziness, tiredness, blurred vision, changes in weight, headache, muscle ache/pain, dry mouth, bad taste in the mouth, stuffy nose, constipation, or change in sexual interest/ability may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.To relieve dry mouth, suck on (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water, or use a saliva substitute.To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: shaking (tremors), nightmares, ringing in the ears, problems urinating, blood in urine, signs of infection (such as such as sore throat that doesn't go away, fever), shortness of breath, stomach/abdominal pain.Get medical help right away if you have any very serious side effects, including: chest/jaw/left arm pain, fainting, fast/irregular heartbeat, seizures, eye pain/swelling/redness, widened pupils, vision changes (such as seeing rainbows around lights at night).This medication may increase serotonin and rarely cause a very serious condition called serotonin syndrome/toxicity. The risk increases if you are also taking other drugs that increase serotonin, so tell your doctor or pharmacist of all the drugs you take (see Drug Interactions section). Get medical help right away if you develop some of the following symptoms: fast heartbeat, hallucinations, loss of coordination, severe dizziness, severe nausea/vomiting/diarrhea, twitching muscles, unexplained fever, unusual agitation/restlessness.Rarely, males may have a painful or prolonged erection lasting 4 or more hours. If this occurs, stop using this drug and get medical help right away, or permanent problems could occur.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking trazodone, tell your doctor or pharmacist if you are allergic to it; or to nefazodone; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: personal or family history of bipolar disorder, personal or family history of suicide attempts, heart disease (such as irregular heartbeat, heart attack), liver disease, kidney disease, blood pressure problems, personal or family history of glaucoma (angle-closure type).This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Trazodone may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using trazodone, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using trazodone safely.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be more sensitive to the side effects of this drug, especially drowsiness, dizziness, and QT prolongation (see above).During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.Since untreated mental/mood problems (such as depression) can be a serious condition, do not stop taking this medication unless directed by your doctor. If you are planning pregnancy, become pregnant, or think you may be pregnant, immediately discuss with your doctor the benefits and risks of using this medication during pregnancy.This medication passes into breast milk. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.A product that may interact with this drug is: digoxin.Taking MAO inhibitors with this medication may cause a serious (possibly fatal) drug interaction. Avoid taking MAO inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine) during treatment with this medication. Most MAO inhibitors should also not be taken for two weeks before and after treatment with this medication. Ask your doctor when to start or stop taking this medication.Other medications can affect the removal of trazodone from your body, which may affect how trazodone works. Examples include azole antifungals (such as itraconazole, ketoconazole), HIV protease inhibitors (such as indinavir), macrolide antibiotics (such as erythromycin), ritonavir, drugs used to treat seizures (such as phenytoin), among others.The risk of serotonin syndrome/toxicity increases if you are also taking other drugs that increase serotonin. Examples include street drugs such as MDMA/"ecstasy," St. John's wort, certain antidepressants (including SSRIs such as fluoxetine/paroxetine, SNRIs such as duloxetine/venlafaxine), among others. The risk of serotonin syndrome/toxicity may be more likely when you start or increase the dose of these drugs.Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, marijuana (cannabis), antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), muscle relaxants, and opioid pain relievers (such as codeine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: painful/prolonged erection, slow/rapid/irregular heartbeat, unusual drowsiness, unusual dizziness, vomiting, trouble breathing, seizures.
NOTES: Do not share this medication with others.Lab and/or medical tests should be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised January 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.